On a Mission to Transform Early Cardiac Diagnostics
Acarix’s vision is to transform early cardiac diagnostics by delivering accessible, easy-to-use acoustic based solutions that provide accurate and timely results to healthcare professionals and patients at point of care, regardless of geographical location or socioeconomic status.
Quickly and Easily Risk Stratify Significant CAD with at least 96% Confidence (Negative Predictive Value)¹
CADScor® System is a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze the patient’s coronary blood flow. The system calculates a patient-specific CAD-score, and couples it with risk factors to rapidly indicate the patient’s risk of significant coronary stenosis for immediate risk stratification, prior to potential secondary evaluation.1 CADScor® System has been used in over 47,000 patient assessments2 and has CE-marking and FDA De Novo clearance.
Use CADScor® System to Risk Stratify Significant CAD in Patients Experiencing Chest Pain or Shortness of Breath*
Non-invasive and radiation free assessment with actionable results
Can help save costs of urgent advance CAD diagnostics in up to 40% of patients3
Allow for immediate risk stratification prior to potential secondary evaluation
Physicians’ Experiences Using CADScor®System
CADScor® System Research, Development and Clinical studies
CADScor® System is based on 15+ years of R&D, covered by 45 patents, approved in Europe with CE-marking and has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD. Multiple clinical studies with over 6,000 patients studied have been published to demonstrate CADScor® System’s performance.
Schedule a Demo of CADScor® System
Schedule a free demo of CADScor® System and learn how you can Risk Stratify significant CAD at point of care.*
Latest Press Releases
- User manual US-FDA v.12.Y, prevalence 10,7%
- Based on commercial patch use since 2017
- Bjerking LH et al. Eur Heart J. Published online September 1, 2024
*Risk Stratify with at least 96% confidence (NPV)